Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation

Courtney M. Rowan, Sophie Paczesny

Research output: Contribution to journalArticle

Abstract

Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.

Original languageEnglish (US)
JournalClinics in Laboratory Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Biomarkers
Stem cells
Graft vs Host Disease
Grafts
Early Diagnosis
Therapeutics

Keywords

  • Biomarkers
  • Graft versus host disease
  • Hematopoietic stem cell transplantation
  • Proteomics

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation. / Rowan, Courtney M.; Paczesny, Sophie.

In: Clinics in Laboratory Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{5070262464a64963bcbabbd223191339,
title = "Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation",
abstract = "Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.",
keywords = "Biomarkers, Graft versus host disease, Hematopoietic stem cell transplantation, Proteomics",
author = "Rowan, {Courtney M.} and Sophie Paczesny",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cll.2018.10.005",
language = "English (US)",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation

AU - Rowan, Courtney M.

AU - Paczesny, Sophie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.

AB - Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.

KW - Biomarkers

KW - Graft versus host disease

KW - Hematopoietic stem cell transplantation

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85058504439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058504439&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2018.10.005

DO - 10.1016/j.cll.2018.10.005

M3 - Article

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

ER -